- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Video
Secukinumab Approved for Plaque Psoriasis in Children, Adolescents
Author(s):
John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.
Video Player is loading.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Larry Eichenfield, MD: Safety, Convenience, and Future Role of Icotrokinra in Treating Adolescent Psoriasis
Andrew Baker, MBA, MPAS, PA-C, Shares Vision for SDPA Leadership
Future Directions for IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis Care
Utility of Head-to-Head Studies in Psoriasis Management
Larry Eichenfield, MD: Icotrokinra Demonstrates Promising Results for Adolescents With Moderate to Severe Plaque Psoriasis
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis
Related Content
